Psychopharmacology of borderline personality disorder

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Psychopharmacology is widely used in the treatment of borderline personality disorder. However, support for this form of treatment has been largely based on case reports, case series, and open-label clinical trials. This evidence-based review examines the most recent randomized controlled trials of psychopharmacology in the treatment of borderline personality disorder, with a goal of highlighting the most promising pharmacotherapy for use in current clinical practice, as well as for future large-scale research testing. The results and limitations of the randomized controlled trial data are presented along with case vignettes illustrating the complexity of the disorder and the heterogeneity of its treatment. To date, there is at least some evidence-based support for the use of antipsychotics (conventional and atypical), monoamine oxidase inhibitors, serotonin reuptake inhibitors, and omega-3 fatty acids in the treatment of borderline personality disorders.

Original languageEnglish (US)
Pages (from-to)225-231
Number of pages7
JournalCurrent Psychiatry Reports
Volume6
Issue number3
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Psychopharmacology
Borderline Personality Disorder
Randomized Controlled Trials
Therapeutics
Monoamine Oxidase Inhibitors
Omega-3 Fatty Acids
Serotonin Uptake Inhibitors
Antipsychotic Agents
Clinical Trials
Drug Therapy
Research

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Psychopharmacology of borderline personality disorder. / Raj, Y (Pritham).

In: Current Psychiatry Reports, Vol. 6, No. 3, 06.2004, p. 225-231.

Research output: Contribution to journalArticle

@article{50fbfefaa12e4c47a7bd7a0b9418057c,
title = "Psychopharmacology of borderline personality disorder",
abstract = "Psychopharmacology is widely used in the treatment of borderline personality disorder. However, support for this form of treatment has been largely based on case reports, case series, and open-label clinical trials. This evidence-based review examines the most recent randomized controlled trials of psychopharmacology in the treatment of borderline personality disorder, with a goal of highlighting the most promising pharmacotherapy for use in current clinical practice, as well as for future large-scale research testing. The results and limitations of the randomized controlled trial data are presented along with case vignettes illustrating the complexity of the disorder and the heterogeneity of its treatment. To date, there is at least some evidence-based support for the use of antipsychotics (conventional and atypical), monoamine oxidase inhibitors, serotonin reuptake inhibitors, and omega-3 fatty acids in the treatment of borderline personality disorders.",
author = "Raj, {Y (Pritham)}",
year = "2004",
month = "6",
language = "English (US)",
volume = "6",
pages = "225--231",
journal = "Current Psychiatry Reports",
issn = "1523-3812",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Psychopharmacology of borderline personality disorder

AU - Raj, Y (Pritham)

PY - 2004/6

Y1 - 2004/6

N2 - Psychopharmacology is widely used in the treatment of borderline personality disorder. However, support for this form of treatment has been largely based on case reports, case series, and open-label clinical trials. This evidence-based review examines the most recent randomized controlled trials of psychopharmacology in the treatment of borderline personality disorder, with a goal of highlighting the most promising pharmacotherapy for use in current clinical practice, as well as for future large-scale research testing. The results and limitations of the randomized controlled trial data are presented along with case vignettes illustrating the complexity of the disorder and the heterogeneity of its treatment. To date, there is at least some evidence-based support for the use of antipsychotics (conventional and atypical), monoamine oxidase inhibitors, serotonin reuptake inhibitors, and omega-3 fatty acids in the treatment of borderline personality disorders.

AB - Psychopharmacology is widely used in the treatment of borderline personality disorder. However, support for this form of treatment has been largely based on case reports, case series, and open-label clinical trials. This evidence-based review examines the most recent randomized controlled trials of psychopharmacology in the treatment of borderline personality disorder, with a goal of highlighting the most promising pharmacotherapy for use in current clinical practice, as well as for future large-scale research testing. The results and limitations of the randomized controlled trial data are presented along with case vignettes illustrating the complexity of the disorder and the heterogeneity of its treatment. To date, there is at least some evidence-based support for the use of antipsychotics (conventional and atypical), monoamine oxidase inhibitors, serotonin reuptake inhibitors, and omega-3 fatty acids in the treatment of borderline personality disorders.

UR - http://www.scopus.com/inward/record.url?scp=3142764603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142764603&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 225

EP - 231

JO - Current Psychiatry Reports

JF - Current Psychiatry Reports

SN - 1523-3812

IS - 3

ER -